Free Trial
NASDAQ:QTTB

Q32 Bio (QTTB) Stock Price, News & Analysis

Q32 Bio logo
$1.58 +0.04 (+2.60%)
As of 10:49 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Q32 Bio Stock (NASDAQ:QTTB)

Key Stats

Today's Range
$1.52
$1.56
50-Day Range
$1.45
$2.33
52-Week Range
$1.38
$53.79
Volume
13,560 shs
Average Volume
222,700 shs
Market Capitalization
$19.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.71
Consensus Rating
Hold

Company Overview

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Q32 Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

QTTB MarketRank™: 

Q32 Bio scored higher than 49% of companies evaluated by MarketBeat, and ranked 634th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Q32 Bio has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Q32 Bio has only been the subject of 3 research reports in the past 90 days.

  • Read more about Q32 Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Q32 Bio are expected to grow in the coming year, from ($12.32) to ($3.84) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Q32 Bio is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Q32 Bio is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Q32 Bio has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Q32 Bio's valuation and earnings.
  • Percentage of Shares Shorted

    15.91% of the float of Q32 Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Q32 Bio has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Q32 Bio has recently decreased by 19.03%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Q32 Bio does not currently pay a dividend.

  • Dividend Growth

    Q32 Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.91% of the float of Q32 Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Q32 Bio has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Q32 Bio has recently decreased by 19.03%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Q32 Bio has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Q32 Bio this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for QTTB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Q32 Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.10% of the stock of Q32 Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 31.32% of the stock of Q32 Bio is held by institutions.

  • Read more about Q32 Bio's insider trading history.
Receive QTTB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Q32 Bio and its competitors with MarketBeat's FREE daily newsletter.

QTTB Stock News Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92% win rate trading system is built to profit in any market – whether Bitcoin is mooning, correcting, or chopping sideways. No more guessing. No more stress. Just precision trades that put you in control.
Leerink Partners Sticks to Its Hold Rating for Q32 Bio (QTTB)
Q32 Bio price target lowered to $15 from $16 at Wells Fargo
See More Headlines

QTTB Stock Analysis - Frequently Asked Questions

Q32 Bio's stock was trading at $3.44 at the start of the year. Since then, QTTB shares have decreased by 55.2% and is now trading at $1.54.
View the best growth stocks for 2025 here
.

Q32 Bio Inc. (NASDAQ:QTTB) released its quarterly earnings data on Tuesday, March, 11th. The company reported ($1.16) earnings per share for the quarter, topping analysts' consensus estimates of ($1.25) by $0.09.

Shares of QTTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Q32 Bio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
3/11/2025
Today
5/07/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:QTTB
Previous Symbol
NASDAQ:QTTB
Fax
N/A
Employees
39
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.71
High Stock Price Target
$100.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+1,504.8%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-112,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$-6,651,000.00
Price / Cash Flow
N/A
Book Value
$22.47 per share
Price / Book
0.07

Miscellaneous

Free Float
10,220,000
Market Cap
$18.78 million
Optionable
N/A
Beta
-0.02
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:QTTB) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners